Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New Drug Price Milestone

Executive Summary

Much like Genzyme’s Ceredase did two decades ago, Novartis’ Zolgensma is setting a new pricing benchmark. The first million-dollar product is launching in the US and it will actually cost more than $2 million.

Advertisement

Related Content

BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A
It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug
Spark Avoids Igniting Pricing Firestorm With Savvy Launch Messages
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
GENZYME APPROACHING 100 PATIENTS ON CEREDASE: $ 20,000-$ 60,000 PER YEAR GAUCHER DISEASE DRUG AVAILABLE FOR WIDER USE AND REIMBURSEMENT AFTER FDA OKAY

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel